drugset / Trial / NCT04347031
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19
RandomizedParallel-groupOpen-labelTreatment
Summary
Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by FSUE "SPC" Farmzaschita " FMBA of Russia (Russia), in comparison with the drug Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection, in the "off-label" mode, to make a decision on the possibility of expanding the indications for use.
Timeline
- Start
- 2020-04-08
- Primary completion
- 2020-11-01
- Completion
- 2020-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 400 mg | Oral |
| Subject | Mefloquine | Unknown | 250 mg | — |
| Background | Azithromycin | Small molecule | — | — |
| Background | Tocilizumab | Monoclonal antibody | — | — |